A reduced risk of relapse with higher serum Leptin was identified among intermediate and advanced stage patients (AML disease stage intermediate/advanced: HR (95% CI): 0.85 (0.74–0.98); p = 0.020. Here, LEP is linked to acute myeloid leukemia.